MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9

References

• Yan X, Song X, Wang Z. Construction of specific magnetic resonance imaging/optical dual-modality molecular probe used for imaging angiogenesis of gastric cancer. Artif Cells Nanomed Biotechnol. 2017;45:399–403.
   PubMed Web of Science ®Google Scholar
• Mohammadian F, Pilehvar-Soltanahmadi Y, Mofarrah M, et al. Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles. Artif Nanomed Biotechnol. 2016;44:1972–1978.
   PubMed Web of Science ®Google Scholar
• Musavi Shenas SMH, Mansoori B, Mohammadi A, et al. SiRNA-mediated silencing of Snail-1 induces apoptosis and alters microRNA expression in human urinary bladder cancer cell line. Artif Nanomed Biotechnol. 2017;45:969–974.
   PubMed Web of Science ®Google Scholar
• Liang SH, Yan XZ, Wang BL, et al. Increased expression of FOXQ1 is a prognostic marker for patients with gastric cancer. Tumor Biol. 2013;34:2605–2609.
   PubMed Web of Science ®Google Scholar
• Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet. 2013;14:535–548.
   PubMed Web of Science ®Google Scholar
• Li X, Yang H, Tian Q, et al. Upregulation of microRNA-17-92 cluster associates with tumor progression and prognosis in osteosarcoma. NEO. 2014;61:453–460.
   Google Scholar
• Wang G, Shen N, Cheng L, et al. Downregulation of miR-22 acts as an unfavorable prognostic biomarker in osteosarcoma. Tumor Biol. 2015;36:7891–7895.
   PubMed Web of Science ®Google Scholar
• Han K, Zhao T, Chen X, et al. microRNA-194 suppresses osteosarcoma cell proliferation and metastasis in vitro and in vivo by targeting CDH2 and IGF1R. Int J Oncol. 2014;45:1437–1449.
   PubMed Web of Science ®Google Scholar
• Liu HT, Xing AY, Chen X, et al. MicroRNA-27b, microRNA-101 and microRNA-128 inhibit angiogenesis by down-regulating vascular endothelial growth factor C expression in gastric cancers. Oncotarget. 2015;6:37458–37470.
   PubMed Web of Science ®Google Scholar
• Li C, Song L, Zhang Z, et al. MicroRNA-21 promotes TGF-beta1-induced epithelial-mesenchymal transition in gastric cancer through up-regulating PTEN expression. Oncotarget. 2016;7:66989–67003.
   PubMedGoogle Scholar
• Cao C, Sun D, Zhang L, et al. miR-186 affects the proliferation, invasion and migration of human gastric cancer by inhibition of Twist1. Oncotarget. 2016;7:79956–79963.
   PubMedGoogle Scholar
• Fu X, Cui Y, Yang S, et al. MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS. Tumor Biol. 2016;37:6477–6483.
   PubMed Web of Science ®Google Scholar
• Guan S, Wang C, Chen X, et al. MiR-613: a novel diagnostic and prognostic biomarker for patients with esophageal squamous cell carcinoma. Tumor Biol. 2016;37:4383–4391.
   PubMed Web of Science ®Google Scholar
• Li B, Xie Z, Li Z, et al. MicroRNA-613 targets FMNL2 and suppresses progression of colorectal cancer. Am J Transl Res. 2016;8:5475–5484.
   PubMed Web of Science ®Google Scholar
• Li D, Li DQ, Liu D, et al. MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer. Cell Oncol (Dordr). 2016;39:139–147.
   PubMed Web of Science ®Google Scholar
• Li X, Sun X, Wu J, et al. MicroRNA-613 suppresses proliferation, migration and invasion of osteosarcoma by targeting c-MET. Am J Cancer Res. 2016;6:2869–2879.
   PubMed Web of Science ®Google Scholar
• Ren W, Li C, Duan W, et al. MicroRNA-613 represses prostate cancer cell proliferation and invasion through targeting Frizzled7. Biochem Biophys Res Commun. 2016;469:633–638.
   PubMed Web of Science ®Google Scholar
• Wu J, Yuan P, Mao Q, et al. miR-613 inhibits proliferation and invasion of breast cancer cell via VEGFA. Biochem Biophys Res Commun. 2016;478:274–278.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu X, Zhu X, et al. MiR-613 suppresses retinoblastoma cell proliferation, invasion, and tumor formation by targeting E2F5. Tumour Biol. 2017;39. doi: 1010428317691674
   Web of Science ®Google Scholar
• Jiang B, Li Z, Zhang W, et al. miR-874 Inhibits cell proliferation, migration and invasion through targeting aquaporin-3 in gastric cancer. J Gastroenterol. 2014;49:1011–1025.
   PubMed Web of Science ®Google Scholar
• Zhang LQ, Sun SL, Li WY, et al. Decreased expression of tumor suppressive miR-874 and its clinical significance in human osteosarcoma. Genet Mol Res. 2015;14:18315–18324.
   PubMed Web of Science ®Google Scholar
• Nohata N, Hanazawa T, Kikkawa N, et al. Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. Br J Cancer. 2011;105:833–841.
   PubMed Web of Science ®Google Scholar
• Garriga J, Bhattacharya S, Calbo J, et al. CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2. Mol Cell Biol. 2003;23:5165–5173.
   PubMed Web of Science ®Google Scholar
• Gordon V, Bhadel S, Wunderlich W, et al. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol. 2010;24:2267–2280.
   PubMed Web of Science ®Google Scholar
• Krystof V, Baumli S, Furst R. Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target. CPD. 2012;18:2883–2890.
   Google Scholar
• Mitra P, Yang RM, Sutton J, et al. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression. Oncotarget. 2016;7:9069–9083.
   PubMed Web of Science ®Google Scholar
• Morales F, Giordano A. Overview of CDK9 as a target in cancer research. Cell Cycle. 2016;15:519–527.
   PubMed Web of Science ®Google Scholar
• Yin T, Lallena MJ, Kreklau EL, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014;13:1442–1456.
   PubMed Web of Science ®Google Scholar
• Liu X, Shi S, Lam F, et al. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. Int J Cancer. 2012;130:1216–1226.
   PubMed Web of Science ®Google Scholar